SCHEMBL694766

SCHEMBL694766

Cc1cc2c[c]cc(-c3cccc(F)c3)c2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
TNKS2 Q9H2K2 1/20 0.37
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
PGR P06401 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
PIM1 P11309 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
NPY5R Q15761 1/20 0.34
GRM5 P41594 1/20 0.34
ACHE P22303 1/20 0.34
CDC7 O00311 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL703221 0.83 MGAM (0.42) MGAMGAASIMGAM2TNKS2
SCHEMBL694686 0.82 PIN1 (0.41) KDM4EHPGDNPSR1ALDH1A1
SCHEMBL699803 0.78 AHR (0.39) KDM4EHPGDNPSR1RXFP1PIM1
SCHEMBL15450902 0.69 MAPK14 (0.49) MGAMGAASIMGAM2TNKS2
SCHEMBL2012945 0.67 ACHE (0.39) MGAMGAASIMGAM2TNKS2
SCHEMBL10304978 0.67 ABL1 (0.47) MGAMGAASIMGAM2TNKS2
SCHEMBL321421 0.67 HTR7 (0.51) MGAMGAASIMGAM2TNKS2
SCHEMBL12488051 0.67 TAAR1 (0.44) KDM4ERXFP1MAPT
SCHEMBL27707563 0.66 TAAR1 (0.40) KDM4EHPGDNPSR1RXFP1PIM1
SCHEMBL11719410 0.66 KDM4E (0.42) GAAKDM4EHPGDPGRADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197450-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-08-02 EP disclosed
WO-2016046130-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-03-31 WO disclosed
EP-2421825-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP disclosed
WO-2010124108-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed